期刊文献+

肺动脉高压的抗炎治疗

Anti-inflammatory therapy in pulmonary arterial hypertension
原文传递
导出
摘要 由各种因素引起的肺动脉高压的根本问题是肺血管重构,但其发病机制尚未完全清楚。炎症反应在肺动脉高压的发病机制中扮演了重要角色已成为共识。近年来,应用多种抗炎药物疗法干预肺动脉高压取得了许多关键进展,为临床治疗提供了新的途径。本文拟就肺动脉高压发病过程中的免疫紊乱及抗炎药物治疗的l临床应用及研究现状进行综述。 Pulmonary arterial hypertension (PAH) is characterized by pulmonary vascular remodeling of the pre-capillary pulmonary arteries. Although the exact pathophysiology remains unknown, there is increasing evidence to suggest an important role for inflammatory mechanism. Recently, many studies show that anti-inflammatory therapies have been effective in PAH, provide a new approach for PAH therapy. This article summarizes the mechanisms and anti-inflammatory therapy of PAH.
出处 《国际呼吸杂志》 2013年第12期931-934,共4页 International Journal of Respiration
基金 基金项目:国家自然科学基金(30971319) 江苏省2010年度普通高校研究生科研创新计划项目(CX10B-326Z)
关键词 肺动脉高压 炎症 抗炎治疗 Pulmonary arterial hypertension Inflammation Anti-inflammatory therapy
  • 相关文献

参考文献28

  • 1Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol, 1994,144:275-285.
  • 2Voelkel NF, Tuder RM, Bridges J, et al. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monoerotaline. Am J Respir Cell Mol Biol, 1994, 11 : 664-675.
  • 3Peinado VI, Barbera JA, Ramirez J, et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol,1998,274(6 Pt 1):L908-L913.
  • 4Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest, 2012,141 : 210-221.
  • 5Soon E, Holmes AM, Treaty CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation, 2010, 122:920-927.
  • 6Humbert M, Monti G, Brenot F,et al. Increased interleukin- 1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med, 1995, 151 : 1628-1631.
  • 7Sanchez O, Marcos E, Perros F, et al. Role of endothelium- derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med, 2007,176 : 1041-1047.
  • 8Quarck R, Nawrot T, Meyns B, et al. Oreactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coil Cardiol, 2009,53 : 1211-1218.
  • 9Sanchez O, Sitbon O, Jais X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest, 2006,130 : 182-189.
  • 10Ogawa A, Nakamura K, Matsubara H, et al. Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation, 2005,112:1806-1812.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部